Tom 18, Nr 1 (2023)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2023-06-12
Wyświetlenia strony
397
Wyświetlenia/pobrania artykułu
13
Problem restenozy i zakrzepicy w stentach wieńcowych II generacji uwalniających lek
Kardiol Inwazyjna 2023;18(1):15-23.
Streszczenie
W dziedzinie kardiologii interwencyjnej w ostatnich latach dokonał się znaczący postęp zarówno w rozumieniu, jak i leczeniu choroby wieńcowej. Słowa stent, czyli, według definicji, „dziurkowanej rurki wszczepianej do naczynia krwionośnego, zapobiegającej ponownemu zwężeniu się naczynia”, po raz pierwszy użył w 1966 roku Weldon. Pierwsze zabiegi na naczyniach wieńcowych wykonano w latach 70. ubiegłego wieku — rok 1977 uznawany jest jako czas narodzin zabiegów przezskórnych na naczyniach wieńcowych (PCI). Wspomniany postęp w technikach PCI, farmakoterapii, jak i technologii produkcji stentów uwalniających lek (DES) przyczynił się do znacznego zmniejszenia częstości występowania zarówno zakrzepicy w stencie, jak i restenozy. Jednakże uwzględniając liczbę wykonywanych PCI rokrocznie, stanowią one (szczególnie restenoza) istotny problem i obciążenie dla systemu ochrony zdrowia. Lepsze poznanie oraz identyfikacja czynników ryzyka restenozy oraz zakrzepicy w stencie pozwala nie tylko na indywidualizację terapii, a także na dalsze ulepszanie/ewolucję technologii produkcji DES.
Słowa kluczowe: stent uwalniający sirolimusgrubość przęsłabiodegradowalny polimer
Referencje
- Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995; 129(1): 146–172.
- Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979; 301(2): 61–68.
- Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology. 1985; 156(1): 73–77.
- Schatz RA, Palmaz JC, Tio FO, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987; 76(2): 450–457.
- Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331(8): 489–495.
- Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331(8): 496–501.
- Foerst J, Vorpahl M, Engelhardt M, et al. Evolution of coronary stents: from bare-metal stents to fully biodegradable, drug-eluting stents. Combination Products in Therapy. 2013; 3(1-2): 9–24.
- Kipshidze NN, Tsapenko MV, Leon MB, et al. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2005; 3(5): 953–968.
- Newsome LT, Kutcher MA, Royster RL. Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. Anesth Analg. 2008; 107(2): 552–569.
- Stefanini GG, Byrne RA, Windecker S, et al. State of the art: coronary artery stents — past, present and future. EuroIntervention. 2017; 13(6): 706–716.
- Iannaccone M, Gatti P, Barbero U, et al. Impact of strut thickness and number of crown and connectors on clinical outcomes on patients treated with second-generation drug eluting stent. Catheter Cardiovasc Interv. 2020; 96(7): 1417–1422.
- Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1): 193–202.
- Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol. 2020; 17(1): 37–51.
- Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2011; 4(5): 543–550.
- Kelly CR, Teirstein PS, Meredith IT, et al. Long-Term safety and efficacy of platinum chromium everolimus-eluting stents in coronary artery disease: 5-year results from the PLATINUM trial. JACC Cardiovasc Interv. 2017; 10(23): 2392–2400.
- Hassan S, Ali MN, Ghafoor B. Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach. J Cardiothorac Surg. 2022; 17(1): 65.
- Kommineni N, Saka R, Khan W, et al. Non-polymer drug-eluting coronary stents. Drug Deliv Transl Res. 2018; 8(4): 903–917.
- Polimeni A, Sorrentino S, Spaccarotella C, et al. Stent thrombosis after percutaneous coronary intervention: from bare-metal to the last generation of drug-eluting stents. Cardiol Clin. 2020; 38(4): 639–647.
- Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344–2351.
- Yang YX, Liu Y, Li XW, et al. Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis. J Thromb Thrombolysis. 2021; 51(3): 682–692.
- Park KW, Hwang SJ, Kwon DA, et al. Korea Stent Thrombosis Investigators. Characteristics and predictors of drug-eluting stent thrombosis: results from the multicenter 'Korea Stent Thrombosis (KoST)' registry. Circ J. 2011; 75(7): 1626–1632.
- Grundeken MJ, Beijk MAm. A narrative review of ultrathin-strut drug-eluting stents: the thinner the better? Heart Int. 2021; 15(2): 84–93.
- Taglieri N, Bruno AG, Ghetti G, et al. Target lesion failure with current drug-eluting stents: evidence from a comprehensive network meta-analysis. JACC Cardiovasc Interv. 2020; 13(24): 2868–2878.
- He Y, Wang R, Liu J, et al. A randomized comparison of the healing response between the firehawk stent and the xience stent in patients with st-segment elevation myocardial infarction at 6 months of follow-up (TARGET STEMI OCT china trial): an optical coherence tomography study. Front Cardiovasc Med. 2022; 9: 895167.
- Adriaenssens T, Joner M, Godschalk TC, et al. Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global european effort). Circulation. 2017; 136(11): 1007–1021.
- Kitahara H, Okada K, Kimura T, et al. Impact of stent size selection on acute and long-term outcomes after drug-eluting stent implantation in de novo coronary lesions. Circ Cardiovasc Interv. 2017; 10(10).
- Räber L, Mintz GS, Koskinas KC, et al. ESC Scientific Document Group. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018; 39(35): 3281–3300.
- Prati F, Romagnoli E, Burzotta F, et al. Clinical Impact of OCT Findings During PCI: The CLI-OPCI II Study. JACC Cardiovasc Imaging. 2015; 8(11): 1297–1305.
- Choi SY, Witzenbichler B, Maehara A, et al. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. Circ Cardiovasc Interv. 2011; 4(3): 239–247.
- Gao L, Lee S, Kim CJ, et al. Incidence and morphological predictors of intrastent coronary thrombus after drug-eluting stent implantation (from a multicenter registry). Am J Cardiol. 2016; 117(3): 369–375.
- Alfonso F, Coughlan JJ, Giacoppo D, et al. Management of in-stent restenosis. EuroIntervention. 2022; 18(2): e103–e123.
- Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100(18): 1872–1878.
- Bil J, Gil RJ, Kern A, et al. Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II. Postepy Kardiol Interwencyjnej. 2018; 14(3): 299–303.
- Tamez H, Secemsky EA, Valsdottir LR, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021; 17(5): e380–e387.
- Wang H, Wang Q, Hu J, et al. Global research trends in in-stent neoatherosclerosis: a CiteSpace-based visual analysis. Front Cardiovasc Med. 2022; 9: 1025858.
- Chieffo A, Foglieni C, Nodari RL, et al. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. Am J Cardiol. 2009; 104(12): 1660–1667.
- Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 80(4): 348–372.
- Hu W, Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front Bioeng Biotechnol. 2022; 10: 1003322.
- Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014; 100(2): 153–159.
- Wańha W, Bil J, Januszek R, et al. Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis (deb-dragon-registry). Circ Cardiovasc Interv. 2021; 14(9): e010868.
- Généreux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. J Am Coll Cardiol. 2014; 63(18): 1845–1854.
- Zhang X, Yang Li, Ju H, et al. Prevalence and prognosis of coronary stent gap detected by multi-detector CT: a follow-up study. Eur Radiol. 2012; 22(9): 1896–1903.
- Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv. 2019; 12(8): e007023.
